津上精密機床(01651.HK):正積極推進浙江平湖新廠房擴產工程
津上精密機床(01651.HK)表示,正積極推進浙江平湖新廠房擴產工程,以迎接新一輪的機床業景氣週期。
為進一步提高產能,集團計劃對工廠廠房進行改造及擴建,預計於明年底完成,2024年1月投入使用,屆時廠房預計產能4,000至4,500台數控精密機床,年產值可達10億元人民幣。
管理層表示,在未來旳中長期將明確發展目標,繼續擴大產能,銳意開拓市場,加快擴大客戶數量,進一步提高市場佔有份額。相信受惠有利政策,中國高端數控機床市場中長期仍處於快速發展的階段,配合集團強化產能的擴張以及產品性價比的提升,未來將取得優異的業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.